Compile Data Set for Download or QSAR
Report error Found 718 Enz. Inhib. hit(s) with all data for entry = 9503
TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386731((2S,4R)-1-(2-(3- acetyl-5-(2- fluoropyrazolo[1,5- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386732((2S,4R)-1-(2-(3- acetyl-5-(2- (trifluoromethyl) py...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386729((2S,4R)-1-(2-(3- acetyl-5-(2- ethylpyrazolo[1,5- a...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386730((2S,4R)-1-(2-(3- acetyl-5-(2-(tert- butyl)pyrazolo...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386727(methyl 2-(6- ((2S,4R)-1-(2-(3- acetyl-5-(2- methyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386728((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrazolo[1.5- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386725((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrazolo[1,5- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386726((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrazolo[1,5- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386723((2S,4R)-1-(2-(3- acetyl-5-(2- cyclopropylpyrazolo[...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386724((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrazolo[1,5- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386721((1R,3S,5R)-2-(2- (3-acetyl-5-(2- cyclopropylpyrazo...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386722((2S,4R)-1-(2-(3- acetyl-5-(2- cyclopropylpyrazolo[...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386719((1R,3S,5R)-2-(2- (3-acetyl-5- (pyrazolo[1,5- a]pyr...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386720((2S,4R)-1-(2-(3- acetyl-5-(2- cyclopropylpyrazolo[...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386717((1R,3S,5R)-2-(2- (3-acetyl-5-(2- cyclopropylpyrazo...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386718((1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrazolo[1,...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386748((2S,4R)-1-(2-(3- acetyl-5-(1- methyl-2-oxo-1,2- di...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386745((2S,4R)-1-(2-(3- acetyl-5-(1-(5- fluoropyrimidin- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386742((2S,4R)-1-(2-(3- acetyl-5-(1- (pyrimidin-2-yl)- 1H...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386740((2S,4R)-1-(2-(3- acetyl-5-(5,6- dihydro-4H- pyrrol...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM472416(US10822352, Comp No. 689 | 2-(2-(3-acetyl-5-(2- me...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386735((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrazolo[1,5- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386736((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrazolo[1,5- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386733((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrazolo[1,5- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386734((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrazolo[1,5- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM472443(US10822352, Comp No. 721 | (2S,4R)-1-(2-(3-acetyl-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386428(US10287301, Compound 722 | 3-acetyl-1-(2- ((2S,4R)...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386759(1-(2-((1R,3S,5R)- 3-((5'-acetyl-2'- chloro-2-fluor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386760(1-(2-((1R,3S,5R)- 3-((5'-acetyl-2'- chloro-2-fluor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386755(US10287301, Compound 710 | (2S,4R)-1-(2-(1- acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386756(US10287301, Compound 711 | (2S,4R)-1-(2-(1- acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386753((S)-1-(2-(3- acetyl-5- (imidazo[1,2- a]pyrimidin-3...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386754((S)-1-(2-(3- acetyl-5- (imidazo[1,2- a]pyrimidin-3...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386751((2S,4R)-1-(2-(3- acetyl-5-(1- cyclopropyl-1H- pyra...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386752((2S,4R)-1-(2-(3- acetyl-5-(1H- pyrazol-4-yl)-1H- i...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386777(5-(3-acetyl-1-(2- ((2S,4R)-2-((6- bromopyridin-2- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386778(5-(3-acetyl-1-(2- ((2S,4R)-2-((6- bromopyridin-2- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386775((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386776((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386773((2S,4R)-1-(2-(3- acetyl-5-(1H- benzo[d]imidazol- 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386774((2S,4R)-1-(2-(3- acetyl-5-(2- (hydroxymethyl) pyri...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386535(US10287301, Compound 475 | (3S,4S)-2-(2-(3- acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386769((2S,5R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM472455(US10822352, Comp No. 732 | (2S,4R)-1-(2-(3- acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386788((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrazolo[1,5- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386785((S)-4-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386688(US10287301, Compound 637 | (1R,2S,5S)-3-(2- (3-ace...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386756(US10287301, Compound 711 | (2S,4R)-1-(2-(1- acetyl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386784((R)-4-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386781((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
US Patent

Displayed 1 to 50 (of 718 total ) | Next | Last >>
Jump to: